Impairment of Cardiac Function and Remodeling Induced by Myocardial Infarction in Rats are Attenuated by the Nonpeptide Angiotensin-(1-7) Analog AVE 0991

Cardiovascular Therapeutics

Volumn 30, Issue 3, 2012, Pages 152-161

  Zeng, Wu Tao ^a   Chen, Wei Yan ^a,b   Leng, Xiu Yu ^a   Tang, Li Long ^a   Sun, Xiu Ting ^a   Li, Cui Ling ^a   Dai, Gang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

AVE 0991; Cardiac function; Myocardial infarction; Remodeling

Indexed keywords

ANGIOTENSIN[1-7][7 DEXTRO ALANINE]; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; MESSENGER RNA; N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL)PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; ARTICLE; CELL SIZE; CONTROLLED STUDY; DRUG EFFECT; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; MALE; MOUSE; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANGIOTENSIN II; ANIMALS; CARDIOMEGALY; CARDIOTONIC AGENTS; COLLAGEN; DISEASE MODELS, ANIMAL; HEMODYNAMICS; IMIDAZOLES; MALE; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOCARDIUM; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; STROKE VOLUME; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84860643125     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2010.00255.x     Document Type: Article

References (43)

1. Braunwald E, Pfeffer MA. Ventricular enlargement and remodeling following acute myocardial infarction: Mechanisms and management. Am J Cardiol 1991;68:1D-6D.
2. Zornoff LA, Spadaro J. Ventricular remodeling after acute myocardial infarction. Concepts, pathophysiology and therapeutic approach. Arq Bras Cardiol 1997;68:453-460.
3. Sun Y. Intracardiac renin-angiotensin system and myocardial repair/remodeling following infarction. J Mol Cell Cardiol 2010;48:483-489.
4. Trindade DC, Trindade RC, Marassi MP, et al. Role of renin-angiotensin system in development of heart failure induced by myocardial infarction in rats. An Acad Bras Cienc 2007;79:251-259.
5. Grobe JL, Mecca AP, Lingis M, et al. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol 2007;292:H736-H742.
6. Grobe JL, Mecca AP, Mao H, Katovich MJ. Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension. Am J Physiol Heart Circ Physiol 2006;290:H2417-H2423.
7. Zeng W, Chen W, Leng X, He JG, Ma H. Chronic angiotensin-(1-7) administration improves vascular remodeling after angioplasty through the regulation of the TGF-beta/Smad signaling pathway in rabbits. Biochem Biophys Res Commun 2009;389:138-144.
8. Santos RA, Castro CH, Gava E, et al. Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor MAS knockout mice. Hypertension 2006;47:996-1002.
9. Santos RA, Ferreira AJ, Pinheiro SV, Sampaio WO, Touyz R, Campagnole-Santos MJ. Angiotensin-(1-7) and its receptor as a potential targets for new cardiovascular drugs. Expert Opin Investig Drugs 2005;14:1019-1031.
10. Vallon V, Heyne N, Richter K, Khosla MC, Fechter K. [7-D-ALA]-angiotensin 1-7 blocks renal actions of angiotensin 1-7 in the anesthetized rat. J Cardiovasc Pharmacol 1998;32:164-167.
11. Ambuhl P, Felix D, Khosla MC. [7-D-ALA]-angiotensin-(1-7): selective antagonism of angiotensin-(1-7) in the rat paraventricular nucleus. Brain Res Bull 1994;35:289-291.
12. Santos RA, Campagnole-Santos MJ, Baracho NC, et al. Characterization of a new angiotensin antagonist selective for angiotensin-(1-7): Evidence that the actions of angiotensin-(1-7) are mediated by specific angiotensin receptors. Brain Res Bull 1994;35:293-298.
13. Wiemer G, Dobrucki LW, Louka FR, Malinski T, Heitsch H. AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium. Hypertension 2002;40:847-852.
14. Santos RA, Ferreira AJ. Pharmacological effects of AVE 0991, a nonpeptide angiotensin-(1-7) receptor agonist. Cardiovasc Drug Rev 2006;24:239-246.
15. Lemos VS, Silva DM, Walther T, Alenina N, Bader M, Santos RA. The endothelium-dependent vasodilator effect of the nonpeptide Ang(1-7) mimic AVE 0991 is abolished in the aorta of mas-knockout mice. J Cardiovasc Pharmacol 2005;46:274-279.
16. Faria-Silva R, Duarte FV, Santos RA. Short-term angiotensin(1-7) receptor MAS stimulation improves endothelial function in normotensive rats. Hypertension 2005;46:948-952.
17. Pinheiro SV, Simoes ESA, Sampaio WO, et al. Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension 2004;44:490-496.
18. Ferreira AJ, Oliveira TL, Castro MC, et al. Isoproterenol-induced impairment of heart function and remodeling are attenuated by the nonpeptide angiotensin-(1-7) analogue AVE 0991. Life Sci 2007;81:916-923.
19. Ferreira AJ, Jacoby BA, Araujo CA, et al. The nonpeptide angiotensin-(1-7) receptor Mas agonist AVE-0991 attenuates heart failure induced by myocardial infarction. Am J Physiol Heart Circ Physiol 2007;292:H1113-H1119.
20. Benter IF, Yousif MH, Anim JT, Cojocel C, Diz DI. Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME. Am J Physiol Heart Circ Physiol 2006;290:H684-H691.
21. Lubel JS, Herath CB, Tchongue J, et al. Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat. Clin Sci (Lond) 2009;117:375-386.
22. Ebermann L, Spillmann F, Sidiropoulos M, et al. The angiotensin-(1-7) receptor agonist AVE0991 is cardioprotective in diabetic rats. Eur J Pharmacol 2008;590:276-280.
23. Benter IF, Yousif MH, Cojocel C, Al-Maghrebi M, Diz DI. Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. Am J Physiol Heart Circ Physiol 2007;292:H666-H672.
24. Bayne K. Revised guide for the care and use of laboratory animals available. American Physiological Society. Physiologist 1996;39:199, 208-211.
25. Moher D, Schulz KF, Altman DG. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001;357:1191-1194.
26. Collister JP, Hendel MD. The role of Ang (1-7) in mediating the chronic hypotensive effects of losartan in normal rats. J Renin Angiotensin Aldosterone Syst 2003;4:176-179.
27. Widdop RE, Sampey DB, Jarrott B. Cardiovascular effects of angiotensin-(1-7) in conscious spontaneously hypertensive rats. Hypertension 1999;34:964-968.
28. Loot AE, Roks AJ, Henning RH, Tio RA, Suurmeijer AJ, Boomsma F, van Gilst WH. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 2002;105:1548-1550.
29. Strawn WB, Ferrario CM, Tallant EA. Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. Hypertension 1999;33:207-211.
30. Langeveld B, van Gilst WH, Tio RA, Zijlstra F, Roks AJ. Angiotensin-(1-7) attenuates neointimal formation after stent implantation in the rat. Hypertension 2005;45:138-141.
31. Li Y, Wu J, He Q, et al. Angiotensin (1-7) prevent heart dysfunction and left ventricular remodeling caused by renal dysfunction in 5/6 nephrectomy mice. Hypertens Res 2009;32:369-374.
32. Davie AP, McMurray JJ. Effect of angiotensin-(1-7) and bradykinin in patients with heart failure treated with an ACE inhibitor. Hypertension 1999;34:457-460.
33. Frangogiannis NG. Targeting the inflammatory response in healing myocardial infarcts. Curr Med Chem 2006;13:1877-1893.
34. Ellmers LJ, Scott NJ, Medicherla S, et al. Transforming growth factor-beta blockade down-regulates the renin-angiotensin system and modifies cardiac remodeling after myocardial infarction. Endocrinology 2008;149:5828-5834.
35. Kaya EB, Ozer N, Deveci OS, et al. The early predictors of ventricular remodeling after myocardial infarction: The role of tumor necrosis factor-alpha. Anadolu Kardiyol Derg 2009;9:84-90.
36. Irwin MW, Mak S, Mann DL, et al. Tissue expression and immunolocalization of tumor necrosis factor-alpha in postinfarction dysfunctional myocardium. Circulation 1999;99:1492-1498.
37. Krown KA, Page MT, Nguyen C, et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 1996;98:2854-2865.
38. Hegewisch S, Weh HJ, Hossfeld DK. TNF-induced cardiomyopathy. Lancet 1990;335:294-295.
39. Bradham WS, Moe G, Wendt KA, et al. TNF-alpha and myocardial matrix metalloproteinases in heart failure: Relationship to LV remodeling. Am J Physiol Heart Circ Physiol 2002;282:H1288-H1295.
40. Berthonneche C, Sulpice T, Boucher F, et al. New insights into the pathological role of TNF-alpha in early cardiac dysfunction and subsequent heart failure after infarction in rats. Am J Physiol Heart Circ Physiol 2004;287:H340-H350.
41. Cangussu LM, de Castro UG, Do PMR, et al. Angiotensin-(1-7) antagonist, A-779, microinjection into the caudal ventrolateral medulla of renovascular hypertensive rats restores baroreflex bradycardia. Peptides 2009;30:1921-1927.
42. Simoes ESA, Bello AP, Baracho NC, Khosla MC, Santos RA. Diuresis and natriuresis produced by long term administration of a selective angiotensin-(1-7) antagonist in normotensive and hypertensive rats. Regul Pept 1998;74:177-184.
43. Hutchins GM, Bulkley BH. Infarct expansion versus extension: Two different complications of acute myocardial infarction. Am J Cardiol 1978;41:1127-1132.